KOSPIBiotech & Pharma000100

Yuhan

₩79,500▼ 4.45%2026-11-18 close
Market Cap
₩5.9T
Turnover
₩14.5B
Volume
180K
Shares out.
73.6M
PER
26.7×
PBR
2.6×
EPS
₩3,110
Dividend Yield
0.72%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩600 per share · Prices as of the 2026-11-18 close

01

Report overview

Lazcluze royalties anchor earnings; pipeline is the test

Yuhan's earnings recovery rests on Lazcluze-linked milestones and royalties plus better core margins, and the pace of royalty growth and follow-on pipeline results are the next checkpoints.

  1. 1

    Operating profit for 2025 was KRW 104.4 billion, up 90.2% year on year, and the 4.8% operating margin is the highest of 2022–2025.

  2. 2

    Q2 2026 revenue of KRW 639.5 billion and operating profit of KRW 66.9 billion reflected the Lazcluze European milestone, and a July 2026 report called them record quarterly levels.

  3. 3

    Q3 2026 operating profit rose 50.8% year on year to KRW 33.2 billion, while profit attributable to controlling shareholders fell 18.3% to KRW 20.6 billion, so the two measures diverged.

  4. 4

    On its Q3 2026 earnings call, the company said Lazcluze royalties would come in below its earlier outlook.

  5. 5

    No new licensing deal has been signed since 2020, and the board reportedly did not finalize a next CEO candidate at its October 28, 2026 meeting.

02

Business structure

Yuhan's operations span its pharmaceutical (drug sales) segment, an overseas business and a healthcare business, while an API-focused subsidiary handles active pharmaceutical ingredients.

The company said its pharmaceutical, overseas and healthcare businesses all grew steadily in the first quarter of 2026, with the overseas business built on raw-material supply still growing at high rates. iM Securities noted in a November 2026 report that Yuhan's own products have gradually risen to 45% of prescription sales within the drug business.

A May 2026 report said the API subsidiary signed a supply contract worth USD 38.076 million with a counterparty. Steady growth in its high-margin lipid-lowering drug is also cited as a profit base. The largest licensing asset is the lung cancer drug Lazcluze (lazertinib), transferred to Janssen Biotech in 2018.

Janssen holds exclusive rights outside Korea and runs global trials, approvals and commercialization, while Yuhan keeps the domestic development and commercialization rights. Total milestones including upfront payments reach USD 950 million, and USD 300 million had been received cumulatively as of May 2026.

Yuhan has also received sales royalties tied to combination-therapy prescriptions since 2024. The drug has reached four continents, which broadens its regional base.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩570B₩22B3.9%
2025Q4₩546.1B₩26.1B4.8%
2026Q1₩526.8B₩8.8B1.7%
2026Q2₩639.5B₩66.9B10.5%
2026Q3₩604.3B₩33.2B5.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.8T₩36B₩90.6B2.0%4.6%23.2%
2023₩1.9T₩56.8B₩136.1B3.1%6.6%33.9%
2024₩2.1T₩54.9B₩70.7B2.7%3.4%36.8%
2025₩2.2T₩104.4B₩194.1B4.8%8.4%36.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 1.78 trillion in 2022 to KRW 2.19 trillion in 2025, growing for three consecutive years from 2023 through 2025 at rates of 4.7%, 11.2% and 5.7%.

Operating profit went from KRW 36 billion in 2022 to KRW 56.8 billion in 2023 (up 57.5%), fell to KRW 54.9 billion in 2024 (down 3.3%), and recovered to KRW 104.4 billion in 2025 (up 90.2%).

The operating margin rose from 2.0% in 2022 to 3.1% in 2023, eased to 2.7% in 2024, and reached 4.8% in 2025, the highest of 2022–2025.

Profit attributable to controlling shareholders was smallest in 2024 at KRW 70.7 billion (down 48.1%) and largest in 2025 at KRW 194.1 billion (up 174.6%), while net profit including non-controlling interests was KRW 185.3 billion in 2025, a different figure.

At its March 2026 general meeting, the company cited a 9.8% cut in R&D spending, milestone inflows from the China launch and steady growth in its high-margin lipid-lowering drug as 2025 drivers.

Operating cash flow rebounded from KRW 54.6 billion in 2024 to KRW 106.2 billion in 2025, and the debt ratio was 36.3% at end-2025 with total equity of KRW 2.36 trillion and total liabilities of KRW 858.6 billion.

In Q1 2026, revenue was KRW 526.8 billion and operating profit was KRW 8.82 billion, down 66.2% from the prior quarter, a drop that analysts in May 2026 linked to the European milestone moving into Q2.

Q2 2026 revenue of KRW 639.5 billion and operating profit of KRW 66.9 billion reflected that milestone, and a July 2026 report called them record quarterly levels.

Q3 2026 revenue was KRW 604.3 billion (up 6.0% year on year) and operating profit was KRW 33.2 billion (up 50.8%), yet profit attributable to controlling shareholders fell 18.3% to KRW 20.6 billion. About 40% of total milestones is paid to Oscotec and Genosco as R&D fees, so inflows do not fully translate into profit. Profit attributable to controlling shareholders over the last four quarters totaled KRW 232.4 billion.

05

Industry analysis

Lazcluze competes in the EGFR-mutated non-small cell lung cancer treatment market. The combination with Johnson & Johnson's Rybrevant (amivantamab) has won approvals in the US, Europe, Japan and China, broadening its global prescription base.

Johnson & Johnson reported combination-therapy sales of USD 257 million in Q1 2026, up 82% year on year. An industry source said the combination's listing as a preferred regimen for EGFR-mutated lung cancer drove prescription growth.

A subcutaneous formulation and a US J-code applied from July 2026 have simplified dosing and insurance billing. The rival Tagrisso monotherapy has a median overall survival of 38.6 months, and Johnson & Johnson said in March 2025 the combination would extend that by at least 12 months.

Overall survival data expected before year-end 2026 are seen as a key variable for prescription speed. In Europe, reimbursement followed the EU approval of December 2024 in the UK, Switzerland, Italy, Germany and Poland during 2026. The company says Lazcluze has entered a phase where royalties grow as sales expand. However, Johnson & Johnson leads global sales, so Yuhan has limited direct control over the pace of expansion.

06

Outlook

In a July 2026 report, the company said it expects solid growth to continue in the second half of 2026. The same report said approvals and commercialization outside the US are proceeding in sequence, so Lazcluze-related royalty income is expected to keep rising.

The timing of the combination's overall survival data, which is expected before year-end, has not yet been set. At a November 2026 forum, the company said it aims to create two of three targeted global blockbuster drugs by 2030 after Lazcluze, with R&D costs covered by its own revenue by 2031.

It holds six clinical-stage candidates excluding Lazcluze and plans to start two more trials between late 2026 and early 2027, reaching eight. iM Securities said in November 2026 that the allergy candidate YH35324 is in a multinational phase 2 trial.

The 2025 value-up plan targeted one licensing deal per year for 2025–2027, but no new licensing result has emerged since 2020.

For shareholder returns, the company plans to cancel 1% of total issued shares by 2027 in stages, and at its March 2026 general meeting it said it would raise dividends per share by more than 30% versus 2023.

07

Valuation

PER
26.7×
PBR
2.6×
ROE
10.2%
EPS
₩3,110
BPS
₩31,963
Dividend per share
₩600

Valuation reads mainly through how much weight the market gives to Lazcluze royalties and pipeline value relative to core operating profit.

Operating profit was KRW 104.4 billion in 2025, and quarterly operating profit swung from KRW 8.82 billion to KRW 66.9 billion in 2026 depending on milestone timing, so profit-based multiples differ by the quarter used. iM Securities cut its target price from KRW 140,000 to KRW 120,000 on November 11, 2026 while keeping a Buy rating, and said it derived the figure by adding pipeline value and stake value to operating value.

NH Investment & Securities presented a target price of KRW 110,000 in a July 6, 2026 report and said a trend rebound would require confirmation of global drug results. A May 2026 report noted that several brokers lowered targets after weak Q1 results and called for structural improvement.

At the March 2026 general meeting, the company proposed raising total dividends and share cancellations together. Because much of profit depends on milestones and royalties with irregular timing, valuation should be read alongside the quarterly royalty trend.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Lazcluze prescriptions and royalties expand

Johnson & Johnson reported Q1 2026 combination sales of USD 257 million, up 82% year on year. A US J-code for the subcutaneous formulation applied from July 2026, simplifying insurance billing. The company expects Lazcluze-related royalty income to keep rising as overseas commercialization widens.

Kiwoom Securities said in a May 2026 report that overall survival data could add momentum to prescription growth.

Milestone receipts and licensing income

Cumulative Lazcluze milestones including upfront payments reach USD 300 million, about one-third of the USD 950 million total. The May 2026 European commercialization milestone of USD 30 million was reflected in Q2 results. Q2 licensing income was reported at KRW 58.9 billion, up 131% year on year.

The company said it aims to join co-development and commercialization with partners to turn candidates into product sales.

Core profitability recovery

The operating margin improved from 2.0% in 2022 to 4.8% in 2025, while 2025 operating profit rose 90.2% to KRW 104.4 billion.

Q3 2026 operating profit was KRW 33.2 billion, up 50.8% year on year. iM Securities pointed to profitable contribution from the healthcare unit and capacity expansion at the API subsidiary as improving core earnings. A rising share of in-house products is also cited as a margin factor.

09

Bear factors

Royalty outlook trimmed

On its Q3 2026 earnings call, the company said Lazcluze royalties would fall below earlier expectations. A weaker exchange rate and slower-than-expected growth were cited as reasons. Some brokers reportedly lowered targets even as results improved. Because Johnson & Johnson leads overseas sales, Yuhan cannot easily control the pace of expansion.

Milestone dependence and one-off swings

Q1 2026 operating profit of KRW 8.82 billion fell 66.2% from the prior quarter, with the European milestone timing moving into Q2 cited as the reason. Q2 results were heavily influenced by milestone inflows.

About 40% of total milestones goes to Oscotec and Genosco as R&D fees, so only part of the revenue remains as profit. Wide quarterly swings make the trend hard to read from quarterly numbers alone.

Pipeline gap and management issues

No new licensing result has emerged since 2020, which raises concern about growth drivers after Lazcluze. The one-deal-per-year target in the 2025 value-up plan has not been met. The board reportedly did not finalize a next CEO candidate on October 28, 2026. Shinyoung Securities said in May 2026 that losses at affiliates weigh on company-wide margin improvement.

10

Risk factors

FX and royalty-structure risk

Lazcluze royalties track sales and are also exposed to currency moves. In Q3 2026 the weaker exchange rate was cited as a reason for lower royalty expectations. Janssen leads sales expansion, so Yuhan cannot directly control the pace. If royalty growth slows, the pace of earnings recovery could slow as well.

Clinical and drug-development risk

Besides Lazcluze, the company holds six clinical-stage candidates and plans to add two to reach eight. New drug development carries long investment periods and failure risk. According to a news report, 2025 R&D spending was about KRW 240 billion against R&D-related income of KRW 99.2 billion, about 41% of cost. Follow-on candidate results will determine how R&D funding is sustained after Lazcluze.

Management continuity and governance risk

Delays in naming the next CEO have raised concern about continuity of the growth strategy. Commentators argue the incoming team must build a business structure that can offset slower Lazcluze growth. Whether the 2025 value-up licensing target is met is tied to the leadership transition. Losses at affiliates are also cited as a drag on company-wide margins.

11

What to watch next

  1. Within 2026 (date not yet set)

    Release of overall survival data for the Lazcluze combination. It is a key variable for prescription speed and royalty growth.

  2. After late 2026 (date not yet set)

    Naming of the next CEO, which will shape continuity of the post-Lazcluze growth strategy.

  3. Second half of 2026 onward (date not yet set)

    Progress of the YH35324 allergy candidate's phase 2 trial and any licensing deal, a test of whether a new licensing result can close the gap.

  4. Around late March 2027

    Filing of the 2026 annual report, the point at which full-year operating margin, R&D spending and profit attributable to controlling shareholders are confirmed.

  5. Around late April 2027 (preliminary results)

    Q1 2027 results, showing how milestone timing and the royalty trend feed into quarterly profit.

12

Overall view

Yuhan's 2025 results showed a recovery, with operating profit of KRW 104.4 billion and a 4.8% operating margin, driven by Lazcluze-linked milestones and royalties together with better core profitability.

Q2 2026 revenue of KRW 639.5 billion and operating profit of KRW 66.9 billion reflected a European milestone, while Q3 operating profit of KRW 33.2 billion came without a comparable milestone and profit attributable to controlling shareholders fell to KRW 20.6 billion.

Bullish factors include prescription growth for the Rybrevant combination, the US J-code and possible overall survival data before year-end. Bearish factors include lower royalty expectations, milestone volatility, the absence of new licensing deals since 2020 and the delay in naming a CEO.

Target prices cited were lowered before being presented, including NH Investment & Securities at KRW 110,000 in July 2026 and iM Securities at KRW 120,000 in November 2026. The next checkpoints are the overall survival data, the 2026 annual report and Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. mt.co.kr
  3. kukinews.com
  4. mt.co.kr
  5. hankyung.com
  6. huffingtonpost.kr
  7. news.bizwatch.co.kr
  8. m.news.nate.com
  9. nasdoc.com
  10. newspim.com
  11. newspim.com
  12. v.daum.net
  13. newspim.com
  14. m.thinkpool.com
  15. etoday.co.kr
  16. news.nate.com
  17. newspim.com
  18. m.thinkpool.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis